clinical trial · NCT06559722
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
Tonghua Dongbao Pharmaceutical Co.,Ltd·phase3·not yet recruiting·n = 510
Type 2 DiabetesInsulin Degludec/liraglutide InjectionXULTOPHY®
brief summary
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.
started
Aug 1, 2024
primary completion
Oct 1, 2025
completion
Feb 1, 2026
last updated
Aug 19, 2024
official title
A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol